(a) - (d) Not applicable.

(e) At the 2012 annual meeting of shareholders of ImmunoGen, Inc. (referred to as "we" or "us") held on November 13, 2012 (the "2012 Annual Meeting"), our shareholders approved an amendment to our 2006 Employee, Director and Consultant Equity Incentive Plan (the "2006 Plan") to increase the number of shares of common stock authorized for issuance thereunder by 3,500,000.

A summary of the material terms and conditions of the 2006 Plan is set forth in our definitive Proxy Statement dated October 2, 2012, filed with the Securities and Exchange Commission on October 2, 2012, under the caption "Amendment to 2006 Employee, Director and Consultant Equity Incentive Plan to Increase the Number of Shares Authorized for Issuance Thereunder by 3,500,000 (Notice Item 3)." Such description is incorporated herein by reference and is qualified in its entirety by reference to the full text of the amended and restated 2006 Plan filed as Exhibit 10.1 to this Current Report on Form 8-K.

(f) Not applicable.

As stated above, the 2012 Annual Meeting was held on November 13, 2012. At the 2012 Annual Meeting, shareholders fixed the number of Directors constituting the full Board of Directors at ten. The voting results were as follows:

For:               72,519,933
Against             1,970,568
Abstain             2,236,153
Broker Non-Votes            0

At the 2012 Annual Meeting, shareholders elected ten Directors as follows:

                                FOR       WITHHELD    BROKER NON-VOTES
Daniel M. Junius             57,573,872   1,054,636         18,098,146
Stephen C. McCluski          57,656,437     972,071         18,098,146
Mark Goldberg, MD            57,669,384     959,124         18,098,146
Dean J. Mitchell             57,666,544     961,964         18,098,146
Nicole Onetto, MD            57,668,970     959,538         18,098,146
Kristine Peterson            57,667,893     960,615         18,098,146
Howard H. Pien               57,437,895   1,190,613         18,098,146
Mark Skaletsky               57,560,345   1,068,163         18,098,146
Joseph J. Villafranca, PhD   57,663,875     964,633         18,098,146
Richard J. Wallace           57,544,629   1,083,879         18,098,146

At the 2012 Annual Meeting, shareholders approved an amendment to the 2006 Plan to increase the number of shares of common stock authorized for issuance thereunder by 3,500,000 as follows:

For:               56,395,969
Against             2,179,467
Abstain                53,072
Broker Non-Votes   18,098,146

At the 2012 Annual Meeting, shareholders approved an amendment to our Restated Articles of Organization to increase the number of authorized shares of common stock from 100,000,000 to 150,000,000 as follows:

For:               69,915,354
Against             6,636,404
Abstain               174,896
Broker Non-Votes            0

At the 2012 Annual Meeting, shareholders voted to approve, on an advisory basis, the compensation paid to the our named executive officers, as described in our proxy statement (the "say-on-pay vote") as follows:

For:               56,318,771
Against             2,217,475
Abstain                92,262
Broker Non-Votes   18,098,146

At the 2012 Annual Meeting, shareholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending June 30, 2013 as follows:

For:               76,151,758
Against               345,670
Abstain               229,226
Broker Non-Votes            0

(d): The following exhibit is being furnished herewith:

Exhibit
No. Exhibit

10.1 2006 Employee, Director and Consultant Equity Incentive Plan, as amended and restated through November 13, 2012